Steven Ryder, Chief Medical Officer of Yarrow Bioscience, Inc., filed a Form 4 on October 30, 2026, reporting the acquisition of a stock option to purchase 113,137 shares of common stock, with a transaction date of October 29, 2026.

Key Highlights

  • Reporting person: Steven Ryder, Chief Medical Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW)
  • Security granted: A Stock Option (Right to Buy) covering 113,137 shares of common stock
  • Exercise price: $20 per share, with the option expiring on October 29, 2036
  • Grant price: $0 (the price of the derivative security as reported in the filing)
  • Transaction code: A (acquired), dated October 29, 2026
  • Vesting schedule: One quarter vests on July 28, 2027; the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service
  • Post-transaction holdings: 113,137 derivative securities beneficially owned directly following the reported transaction

Steven Ryder's Stock Option Award at Yarrow Bioscience

According to the filing, Steven Ryder, serving as Chief Medical Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW), received a stock option on October 29, 2026, granting him the right to purchase 113,137 shares of the issuer's common stock at an exercise price of $20 per share. The option is classified as a derivative security acquired (transaction code A) and is held directly by the reporting person.

The filing discloses that the option expires on October 29, 2036. The vesting terms, as explained in the filing's footnote, provide that "one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date." No shares of non-derivative common stock were reported as acquired or disposed of in Table I of this filing.

The Form 4 was signed by Tyler Zeronda as attorney-in-fact for Steven Ryder and filed on October 30, 2026. Following the reported transaction, Ryder beneficially owns 113,137 derivative securities on a direct basis, as stated in the filing. No prior holdings in derivative or non-derivative securities were reported in this filing.

What Was Disclosed

Yarrow Bioscience's Chief Medical Officer, Steven Ryder, disclosed the acquisition of a stock option covering 113,137 shares of common stock at a $20 exercise price, granted October 29, 2026, with a ten-year term and a multi-year vesting schedule tied to continued service.